Expression of the prostate cancer metastasis suppressor geneKAI1 in primary prostate cancers: a biphasic relationship with tumour grade

✍ Scribed by Bouras, Toula; Frauman, Albert G.

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 244 KB
• Volume: 188
• Category: Article
• ISSN: 0022-3417
• DOI: 10.1002/(sici)1096-9896(199908)188:4<382::aid-path365>3.0.co;2-o

✦ Synopsis

The KAI1 gene, isolated from human chromosome 11p11.2, has been implicated as a prostate cancer metastasis suppressor gene. Recent studies have demonstrated that the expression of KAI1 protein is reduced in metastases of human prostate cancers and is inversely correlated with tumour grade. The objectives of the present work were to determine whether alterations of KAI1 at a genetic level in localized prostate cancers correlate with degrees of differentiation. This paper reports the application of semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Southern analysis to two different regions of the KAI1 gene on 35 microdissected primary prostate cancer specimens and demonstrates a biphasic pattern of KAI1 expression according to histological grade. KAI1 mRNA, relative to the housekeeping gene -actin, was elevated in low-grade primary prostate cancer (2•7 0•4) compared with non-malignant (hyperplastic) prostatic tisues (0•92 0•02, p<0•05), yet reduced in high-grade primary cancers (0•61 0•11, p<0•05). These data demonstrate, for the first time, that KAI1 is biphasically expressed in primary prostate cancers and suggest that hyperexpression of KAI1 in low-grade prostate cancer may be associated with restraint of tumour progression, whereas a relative decrease in KAI1 gene expression may accompany more aggressive cancers through loss of such restraint. This differential expression of the metastasis suppressor gene KAI1 in primary prostate cancers may have important prognostic implications for the development of subsequent metastases. Should the level of KAI1 in primary prostate cancer be correlated with patient outcome such information may, in the future, enable more intensive adjuvant therapy to be directed to those patients identified to be at greatest risk of metastasis.